Net profit of Sequent Scientific reported to Rs 2.61 crore in the quarter ended September 2024 as against net loss of Rs 8.38 crore during the previous quarter ended September 2023. Sales rose 6.56% to Rs 368.65 crore in the quarter ended September 2024 as against Rs 345.97 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales368.65345.97 7 OPM %10.614.37 - PBDT29.324.20 598 PBT12.22-11.16 LP NP2.61-8.38 LP Powered by Capital Market - Live News

Sequent Scientific has approved the issue and allotment of 120,000 Equity Shares of Rs. 2/- each fully paid to two Employees at an exercise price of Rs. 86/- per equity share on exercise of the options granted to them under SeQuent ESOP 2020. Powered by Capital Market - Live News

Sequent Scientific has allotted 60,000 equity shares under ESOP on 16 October 2024. Consequent to the allotment of the aforesaid equity shares, the issued and the paid-up equity share capital of the Company will increase from Rs. 49,91,63,990/-consisting of 249581995 Equity Shares of Rs. 2/- each to Rs. Rs. 49,92,83,990/-consisting of 249641995 Equity Shares of Rs. 2/- each.Powered by Capital Market - Live News

Sequent Scientific announced that the Annual General Meeting (AGM) of the company will be held on 17 September 2024.Powered by Capital Market - Live News

Sequent Scientific announced its receipt of prequalification (PQ) approval from the World Health Organization (WHO) for Albendazole, Active Pharmaceutical Ingredient (API). This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using our API. Mepro`s Chewable formulation is the first global approval of its kind by the WHO PQ. Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middle income countries. The WHO prequalification recognizes Sequent Scientific`s commitment to stringent international standards in the production of Albendazole API, ensuring efficacy, safety, and quality. The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale,� said Rajaram Narayanan, MD & CEO of Sequent Scientific.Powered by Capital Market - Live News